Typifying the former, glucagon-like peptide-1 (GLP-1) receptor agonist administration both to healthy volunteers (54) and to patients with type 2 diabetes (55) acutely diminishes postprandial secretion of apoB-48-containing TRL, while GLP-2 administration does just the opposite (56). This evidence concerns the gene GCG and type 2 diabetes mellitus.